Naval Gustad Daver MD

Hematologic Oncology

Physician

4505 Beech StreetBellaire, TX 77401
Phone+1 713-794-4392

Dr. Daver is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Daver's full profile Already have an account?

Education & Training

Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2008 - 2011
Baylor College of MedicineResidency, Internal Medicine, 2005 - 2008
Grant Medical CollegeClass of 2004

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2011 - 2027
OK State Medical License 2020 - 2021
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015

Clinical Trials

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
COMPLETED
PHASE2
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm Start of enrollment: 2013 Mar 13
COMPLETED
PHASE2
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Start of enrollment: 2013 Jul 18
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.
Nicholas J Short, Hagop Kantarjian, Naval Daver, Roberta S Azevedo, Omer Karrar
Blood Advances. 2026-09-08
Treatment of older adults with newly diagnosed-mutated AML: focus on lower-intensity triplet regimens.
Sankalp Arora, Naval Daver, Farhad Ravandi, Nicholas J Short
Expert Review of Hematology. 2026-08-18
Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.
Aziz Farhat, Georgina El Hajjar, Hagop Kantarjian, Koji Sasaki, Nicholas J Short
Cancer. 2026-08-15

Abstracts/Posters

Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-P...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Treating Acute Myeloid Leukemia: Case Challenges and Emerging Therapies
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Inside ASH25 with Talha BadarDecember 9th, 2025
MD Anderson Unveils Breakthroughs in Blood Cancer TreatmentDecember 9th, 2025
Immunotherapy-Linked ADC Offers Hope for Hard-to-Treat Blood CancersDecember 8th, 2025